stock-detail (LIXT)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/17/2017 06:18 am

Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting

3/9/2017 03:03 pm

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced that a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated ...

First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research

1/4/2017 04:04 pm

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced the publication online of Phase 1 results of its novel anti-cancer compound in Clinical Cancer Research, entitled "Safety, tolerability, and preliminary ...

Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors

6/7/2016 01:03 pm

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, ...

Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

2/3/2016 03:00 pm

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced that neuroscientists at the French Institute of Health and Medical Research using a mouse model of depression have identified protein phosphatase 2A as a potential ...

Lixte Completes Private Placement of Convertible Preferred Stock

1/25/2016 03:03 pm

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common ...

Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

1/5/2016 01:00 am

[PR Newswire] - EAST SETAUKET, N.Y., Jan. 5, 2016 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT) announced last week that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.

Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

12/30/2015 02:03 pm

[PR Newswire] - EAST SETAUKET, N.Y., Dec. 30, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte.

Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity

11/6/2015 05:03 pm

[PR Newswire] - EAST SETAUKET, N.Y., Nov. 6, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT) announced today that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, on November 6.